title: [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
abstract: OBJECTIVE
  The first-line adjuvant chemotherapy regimens of ovarian cancer mainly include TC (paclitaxel combined with carboplatin) and PC (cisplatin combined with cyclophosphamide) protocols. This study was to investigate the correlation of P53 expression to treatment outcome of ovarian cancer patients received the above 2 protocols, and explore the predictive value of P53 expression in selecting chemotherapy regimen.
  
  
  METHODS
  Records of 53 patients with advanced epithelial ovarian cancer (stage IIIc), treated with TC or PC regimen, were analyzed retrospectively. The expression of P53 was detected by immunohistochemistry. The complete response (CR) rate and progression-free survival (PFS) were compared between TC and PC groups according to P53 status.
  
  
  RESULTS
  Of the 53 patients, 22 were P53 positive, of which 13 received TC regimen and 9 received PC regimen; the CR rate was slightly higher in TC group than in PC group (76.9% vs. 33.3%, P=0.054), and PFS was significantly longer in TC group than in PC group (102 weeks vs. 43 weeks, P=0.040). In the subgroup of P53-negative patients, TC group had similar CR rate and PFS to PC group. Multivariate analysis showed that the size of residue was an independent prognostic factor.
  
  
  CONCLUSIONS
  P53 detection may play a role in selecting first-line chemotherapy for advanced epithelial ovarian cancer patients: TC regimen is preference for P53-positive patients, PC regimen may be a choice for P53-negative patients. These recommendations should be tested in further trails with large samples.
authors.affiliation: Department of Obstetrics and Gynecology, Beijing Hospital, Beijing 100730, P. R. China. sparkling8027@sina.com
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Zhao
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Shu-Rong
authors.initials: SR
authors.lastname: He
authors.forename: Li
authors.initials: L
authors.lastname: Yang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D011237:Predictive Value of Tests; D012074:Remission Induction; D012189:Retrospective Studies; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*
chemical_list: D016159:Tumor Suppressor Protein p53; D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin